List of Regenerative Medicine Companies with Phase 2 Active Clinical Trial - 60

AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy.

Aegle Therapeutics Corp. is a clinical-stage biotechnology company developing novel extracellular vesicle (“EV”) therapies to address rare and serious diseases and disorders with significant unmet medical needs. Aegle’s proprietary platform technology safely isolates native extracellular vesicles (“EVs”) from stem cells. These EVs carry complex assemblies of biologic molecules such as proteins and nucleic acids that can induce a wide variety of effects in recipient cells, including the promotion of regenerative healing, while reducing inflammation and modulating the immune system. Aegle’s EV therapy has the potential to treat a broad range of indications in multiple therapeutic areas, including dermatology, immunology-based diseases, protein deficient disorders and others.

Ageless Biotech (ABT) is in the development of discardable, minimally manipulated umbilical tissue based regenerative medicine biologics to address all forms of Osteoarthritis via intra-articular procedures in cooperation with leading scientists and medical professionals. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives. We believe that the formation of life itself is contained within after birth tissues. ABT believes that it is morally, religiously and politically acceptable to use afterbirth materials that would be considered discardable in virtually every country. Furthermore, we believe this to be the right course to addressing problems that a vast majority of the population will face at some point during their lifespan.

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Amnio Technology is an industry leader in the development and manufacture of amnion-derived technologies. Amnio Technology manufactures high-quality, amnion-derived technologies for clinical use.

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, our DFU Phase 2 study is ongoing in Italy, Germany and Poland. Venous Ulcers and other ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a Biosynthetic Wound Matrix, in the United States.

Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen’s comprehensive portfolio of products focuses on helping patients touch, run, feel, kiss, smile and hug—some of the many things healthy peripheral nerves allow us to do.

Axolotl Biologix, located in Arizona is a dynamic biotech company focused on developing and producing human biologics and biological-related products to reduce inflammation and foster regeneration for many conditions that affect patients, including orthopedic, wound care, cosmetic and more. Axolotl is currently negotiating partnerships with universities and research hospitals to find ways to improve current technologies and procedures to improve patients’ quality of life.

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's Helix™ transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 100,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

BRIM is a clinical-stage company developing novel peptide treatments for hard-to-treat diseases. BRIM’s first-in-class assets are based on its innovative stem cell regenerative PDSP technology platform, which has the potential to be effective in multiple therapy areas and indications.

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

Celltex Therapeutics Corporation is a Houston, Texas-based biotechnology company focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (MSCs).

Collagen Matrix is a biotechnology company that specializes in developing medical devices and products for regenerative medicine using collagen as a key component.

Creative Medical Technology Holdings, Inc., formerly Jolley Marketing, Inc., is a clinical-stage company. The Company conducts its business operations primarily through its subsidiary, Creative Medical Technologies, Inc. (CMT). The Company is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility, miscarriages and related issues. CMT focuses on completing the testing of its erectile dysfunction (ED) treatment and, if warranted, marketing treatment kits under the name Caverstem to physicians for use with their patients suffering from ED. CMT also intends to test and, if warranted, market licensed stem cell products under its infertility technology license. Procedures for use of the Company's ED stem cell treatment consist of a one-hour out-patient visit in a physician's office. The physician would harvest a patient's bone marrow from the hip using local anesthetic and separate the stem cells using a cell separator.

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Advancing regenerative medicine through the development of a natural biomaterial that restores mother nature’s template to treat disease and injury. ECM scaffolds, in solid form, have been successfully used in more than 10 million human patients to repair a variety of body systems such as musculoskeletal tissues, cardiovascular structures, and non-healing skin wounds, among others. These products have all received FDA clearance. ECM Therapeutics'​ patented ECM hydrogel technology allows for expanded, less invasive applications in multiple disease areas. The first clinical product, EsophaGel, treats Barrett’s esophagus, a precancerous condition that currently has no effective therapy.

Embody, Inc. is a commercial-stage company pioneering the next generation in collagen-based tendon and ligament healing for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.

Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex's innovations focus on resetting the body's metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the ReCET System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression. Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.

EpiBone is a revolutionary bone reconstruction company that allows patients to "grow their own bone". EpiBone's pioneering technology utilizes a scan of the patient's bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.

弊社は、バイオ革命によって急速に発展し始めている再生医療分野において、体性幹細胞再生医薬品/iPSC再生医薬品の研究開発を行っているバイオベンチャーです。2015年6月には東証マザーズに上場。再生・細胞医薬品の開発・製造を世界で先駆けて取り組み、病で苦しむ患者さんに治療法を提供し希望を届けることを目標としています。 Our company is a bio venture which is doing R & D of somatic stem cell regenerating medicine / iPSC regenerating medicine in the regenerative medicine field which is rapidly developing by the bio-revolution. We were listed on TSE Mothers in June 2015. Our long-term object is to deliver hope to patients suffering from illness by providing treatment methods by pioneering the development and manufacture of regeneration and cellular medicines worldwide.

InGeneron is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to validate our technology as a disease-modifying treatment. Based on more than 20 years of research, InGeneron is dedicated to developing therapies supported by clinical evidence and approved by the FDA.

Innovative BioTherapies (IBT) is a small biotechnology company located in Ann Arbor, MI, focused on developing medical devices to solve unmet medical needs.

InSoma Bio is a company that borrows nature's own designs to develop unique products for reconstructive plastic surgery. Their product enables surgeons to use a person's own tissues to enhance the stability of autologous fat grafts and solve problems in tissue engineering and regenerative medicine.

KiOmed Pharma is a biotechnology company based in Belgium that focuses on developing, manufacturing, and distributing chitosan-based medical devices. The company, a spinout from KitoZyme, utilizes exclusive natural chitosan chemistry to create solutions for high-impact medical conditions, particularly in osteoarthritis, dermatology, and ophthalmology. Headquartered in Herstal, Liège, KiOmed Pharma emphasizes therapeutic innovations through its proprietary KiOmedine® technology platform. One of its key products is KioMedine(vs)one, a single-injection soft implant designed to relieve pain and improve mobility in knee osteoarthritis patients. The company is also developing additional products targeting joint health, skin aging, and eye-related disorders. KiOmed Pharma maintains a commitment to biocompatibility and safety by using non-animal-derived chitosan in its formulations. In April 2024, KiOmed Pharma formed a strategic alliance with Aptissen to globally commercialize KioMedine(vs)one, enhancing patient access to its treatments while generating revenue through royalties and milestone payments. Under the leadership of CEO Houtaï Choumane, the company aims to create long-term value and improve patient outcomes in chronic diseases.

We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. We are currently conducting Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS), which is the current exception to our focus on aging. Our mission is to advance Lomecel-B™ and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging – a period known as healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-B™ addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.

LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis’ lead preclinical program is focused on liver regeneration for patients with end stage liver disease. Other therapeutic targets for organ regeneration include the thymus, pancreas, and kidney. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania.

MEDIPOST is founded in 2000, and today MEDIPOST is leading the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012. MEDIPOST operates the largest private cord blood bank “CELLTREE®” in Korea with over 255,000 units of private cord blood units under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD). MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit)” PNEUMOSTEM® (allogeneic Umbilical Cord Blood-derived MSCs) for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants, completed the first-in-human Phase I safety trial in Korea and the randomized, placebo-controlled Phase II clinical trial is ongoing in Korea. Phase I/II clinical trial in the U.S. has been completed confirming safety with positive efficacy signals. MEDIPOST’s 2nd generation human Umbilical Cord Blood-derived Mesenchymal Stromal Cell (hUCB-MSC) pipeline code named SMUP-IA-01 is an off-the-shelf intra-articular injectable cell product for the patients with early to mid-stage knee osteoarthritis (OA).

MIMEDX Group is a biotechnology company that specializes in regenerative medicine and tissue engineering products.

NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.

Nexcella, Inc. is a Los Angeles, California based clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our lead candidate, next generation BCMA-targeted CAR-T NXC-201 for relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma, has produced 100% and 95% response rates in each indication, respectively, as of December 10, 2023 across 72 patients. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma. We believe NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T, enabling faster return home for patients. Expansion into autoimmune indications is planned. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need. To learn more about Nexcella, Inc. visit us at www.nexcella.com.

OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. Website: www.ossdsign.com Newsroom: https://news.cision.com/ossdsign-ab (Always consult Instructions for Use which accompany the products for complete indications, contraindications, warnings and precautions.)

Building a Healthier Future Our mission is to improve the health, vitality, and longevity of human beings through bioengineering. Who We Are At Ossium, we believe that science is humanity’s best weapon in the fight against disease, and we embrace the challenge of mobilizing the world’s healthcare ecosystem to win that fight. In pursuit of this goal, we empower our employees, maintain the highest standards of excellence, and are a force for good. PRINCIPLES The values we live by Impact We are mission-driven and results-oriented. We believe that a healthier world is a better one and that our work should drive positive change. Truth Embracing the truth empowers us to learn from both our successes and our mistakes. We follow the data wherever it leads. Ownership We hold ourselves and each other to the highest bar. We care deeply about the work we do and know that even the smallest details can make a difference.

Pelage is a clinical-stage regenerative medicine company developing novel treatments for hair loss, including androgenetic alopecia. Based on discoveries in stem cell biology made by Pelage's scientific co-founders, the company's novel approach is designed to reactivate dormant hair follicle stem cells and restore the body's ability to grow hair naturally.

Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019. There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan. However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.

Regenerative Patch Technologies LLC (RPT) is a CA-based biotechnology company focused on the development of stem cell-based therapies designed to reverse blindness caused by advanced dry age related macular degeneration (AMD).

RevBio was started with one goal in mind—to end medicine's 50 year search for a biocompatible bone adhesive. Effective for bone-to-bone as well as bone-to-metal wet field applications, Tetranite® is a revolutionary biomaterial that promises to transform bone repair—for both patients and clinicians. Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm's secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability. The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices. Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.

Rion is a clinical-stage regenerative medicine company focused on developing innovative exosome therapeutics that are clinically impactful, accessible, and practical for any patient, anywhere. Rion has developed Purified Exosome Product (PEP), an innovative biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine.

RTI Surgical (RTI) is a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine. We are expert partners to Original Equipment Manufacturers (OEMs), working with them to identify clinical problems and develop customized solutions that promote healing, accelerate recovery, and help prevent complications. We focus on specialized clinical segments, including breast and plastic surgery, sports medicine and orthopedics, and neuro and spine surgery. Our Mission is to enhance patients' lives by creating the best clinical outcomes through innovative, high-quality medical solutions.

Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.

Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies. Our highly pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immuno-suppression. Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.

Silver Creek Pharmaceuticals, Inc. is a Biotechnology company located in San Francisco, California, United States. We are harnessing the therapeutic potential of growth factors in a new class of biological molecules, to treat acute organ injuries.

Spiderwortisdeveloping a novel biomaterial that will offer new avenues in 3D in vitro research and in regenerative medicineusing plant derived cellulose to create a variety of scaffold architectures.

Taiwan Biotech Therapeutics is a clinical-stage biotech company focusing on developing novel cell therapies. Our proprietary technology platforms enable us to perform safe and effective cell engineering, making our cell products more potent than conventional cell therapies.

Telios Pharma, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in developing therapies for mast cell-mediated inflammatory diseases. Founded in 1993, the company focuses on small-molecule drugs and has a team of 51 to 100 employees. Its annual revenue is estimated between $10 million and $25 million. The company's pipeline includes innovative Bruton’s tyrosine kinase (BTK) inhibitors. Notable candidates are TL-925, a topical eye drop for dry eye disease currently in Phase 2 trials, and M-7583, an oral BTK inhibitor for primary myelofibrosis. TL-925 has shown promising results, providing rapid relief from symptoms and significant improvements in clinical measures. Telios Pharma aims to address significant unmet needs in both dry eye disease and myelofibrosis, targeting markets with limited existing therapies.

Tempo Therapeutics is a biotechnology company that specializes in tissue engineering using proprietary MAP material science technology to build functional tissue and organs within patients in real time for disease treatment.

Developed a computational platform that converts recombinant proteins intomaterial-binding variants that can be used to coat implants, devices, and injectable carriers.

Although our primary product is high-quality human amniotic tissue grafts, we are really in the business of helping people. Tides Medical® sources and acquires donated placentas to make advanced skin substitutes available to the patients who need them. Then we work with physicians and their staff to help them navigate the complex reimbursement process. Our goal in providing these advanced products and expert service is that we will remove the barriers that might prevent patients from accessing the full range of treatment options they deserve. It’s a challenge that our team takes personally.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

Vaccinex is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Our lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.

We are the regenerative medicine company that develops and delivers innovative allograft solutions designed to support the body’s healing and regenerative potential, ultimately improving patient outcomes and quality of life. The underpinnings of our regenerative medicine solutions technology date back 50 years to the founding of The University of Miami Tissue Bank in 1970. We experienced multiple firsts in clinical and scientific achievement leading up to 2014, when VIVEX acquired the University of Miami Tissue Bank. This acquisition streamlined our strategic plan to focus on new regenerative medicine solutions, research and development, expansion of manufacturing capabilities, and sales and marketing efforts.

Volumina Medical is a multi-award-winning start-up active in the field of medical devices supported by a solid network of investors. The company develops breakthrough innovations for plastic and reconstructive surgery. The first product is an implantable polymeric biomaterial and targets the regeneration of soft tissue of the human body which are damaged after tumor excision, genetic malformation or trauma.

Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. Wugen is based out of St. Louis, Missouri and San Diego, California.

Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

ZimVie is a global leader in dental implants and spine innovations. Advancing clinical technology foundational to restoring daily life.